Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Table 1

Main eligibility criteria.

Histologically confirmed advanced prostatic carcinoma
Progression while on D or within 60 days after the last D dose
A positive bone scan and a ≥25% increase in PSA in comparison with baseline
New metastatic lesions revealed by a bone scan
A ≥25% increase in bidimensionally measurable tumor mass
ECOG PS of ≤2
Leukocytes ≥3000/mm^3, haemoglobin ≥ 10 g/dL, platelets ≥100.000/mm^3
Serum creatinine ≤ 2.0 mg/dL; serum bilirubin ≤ 2.0 mg/dL